Sarah Mougalian, MD

Assistant Professor of Medicine (Medical Oncology); Assistant Professor in Medicine (Medical Oncology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Yale Cancer Center: Breast Center

Yale Medicine

Board Certifications

  • Internal Medicine AB of Internal Medicine (2009)

  • Medical Oncology AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Breast - Female, Breast A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Breast - Female, Breast - Male A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Colon, Breast Medication Adherence in Patients Treated with Capecitabine
Breast - Female, Phase I A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
Breast - Female, Breast - Male A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Breast - Female, Breast - Male A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Breast - Female, Breast - Male A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Breast - Female Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Breast - Female, Breast - Male A Phase I/II Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer that Overexpresses Functional Na/I Symporter
Breast - Female Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Breast - Female, Breast - Male A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Breast - Female, Breast - Male Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer
Breast - Female, Breast - Male S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
Breast - Female, Breast - Male Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Breast - Female A Safety Study of SGN-LIV1A in Breast Cancer Patients
Breast - Female, Breast - Male Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Breast - Female, Breast - Male Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Edit this profile

Contact Info

Sarah Mougalian, MD
Patient Care Location
Yale Cancer CenterYale New Haven Hospital
20 York Street, Ste North Pavilion 1

New Haven, CT 06510
View on map...
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06510

Curriculum Vitae